<DOC>
	<DOCNO>NCT00406718</DOCNO>
	<brief_summary>This study determine comparative effectiveness two system design improve medication adherence people schizophrenia .</brief_summary>
	<brief_title>Improving Adherence Oral Antipsychotic Medications People With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia severely debilitate mental disorder . People schizophrenia often experience unusual thought perception , decreased pleasure everyday life , difficulty function social situation . Antipsychotic medication show effective improving symptom schizophrenia . Poor adherence medication , however , lead re-hospitalization , impede process recovery , contribute high cost associate schizophrenia treatment . Studies show PharmCAT , cognitive adaptive training specifically target medication adherence , effective improve adherence outcome people schizophrenia . The Med-eMonitor™ new pill device able alert patient take medication , take wrong medication , take medication wrong time . The device also record side effect complaint send store information treatment staff . The capability Med-eMonitor™ eliminate need weekly home visit necessary PharmCAT program , may make treatment easily available individual remote rural setting . This study compare effectiveness PharmCAT , Med-eMonitor™ , standard treatment improve medication adherence treatment outcome people schizophrenia . Participants study randomly assign one follow treatment group : ( 1 ) PharmCAT ; ( 2 ) Med-eMonitor™ ; ( 3 ) standard treatment . Participants Group 1 receive weekly home visit case manager . These visit specifically target medication adherence . Participants Group 2 use Med-eMonitor™ device . Data record device send electronically study staff . Participants Group 3 keep Med-eMonitor™ device home throughout study use medication reminder function . The device record medication take . All participant report study site study entry Months 4 , 7 , 10 measure symptom , function , social activity , relationship .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder accord DSMIV criterion , determine basis Structured Clinical Interview Diagnosis ( SCIDP ) Receiving treatment oral atypical antipsychotic medication clozapine ( e.g. , risperidone , olanzapine , quetiapine , aripiprazole , ziprasidone , others FDA approve ) Assumes responsibility take medication Able provide evidence stable living environment ( e.g. , individual apartment , family home , board care facility ) within 3 month prior study entry plan move next year Intact visual auditory ability determine computerized screening battery Ability read 5th grade level higher base upon score Wide Range Achievement Test ( WRAT ) Able understand complete rating scale neuropsychological test Working telephone present home History significant head trauma , seizure disorder , mental retardation Alcohol drug abuse dependence within 3 month prior study entry Currently treat assertive community treatment ( ACT ) team History violence within 1 year prior study entry Any hospitalization within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Medication Adherence</keyword>
	<keyword>Psychosocial Treatment</keyword>
	<keyword>Cognitive Adaptation Training</keyword>
	<keyword>Med-e Monitor</keyword>
	<keyword>Adaptive Function</keyword>
</DOC>